Alentis Therapeutics AG

Alentis, a biotech-start-up, is discovering and developing first-in-class medications to treat advanced liver diseases such as fatty liver, fibrosis, cirrhosis and hepatocellular carcinoma, which have high unmet medical needs. Alentis lead project is a mAb targeting a novel MoA, called Claudin-1, that is central in advanced liver fibrosis and that may reverse the course of disease progression. In addition there is a suggested role of Claudin-1 in liver cancer. Alentis is expanding its pipeline using its proprietary discovery platform that enables the identification of novel targets and biomarkers as well as revealing new drug candidates.